In 1990 study in San Diego, CA the 5 active subjects with allergic rhinitis had a lowered total serum IgE from Day 0 to niacin Day 90 while 4 placebo subjects, (2 with allergic rhinitis, 1 with asthma and 1 with both), had flat or increased IgE levels.4 In a randomized, double-blind, placebo controlled study of symptoms and serum IgE levels in San Diego, CA in mid-1991, subjects had allergic rhinitis and/or vitamin asthma. Serum was drawn at Day 0 and Day 30. Seven of the 10 active treated subjects had a reduction in total serum IgE levels. In 10 placebo treated subjects, 5 had levels of total serum IgE that stayed the same (plus or minus 5%), 3 decreased and niacin 2 increased.5 Statistical analysis of the open-label study as well as the double-blind randomized placebo controlled study vitamin have shown a significant effect of vitamin B12 in lowering serum IgE concentrations.

A niacin new HAY FEVER breakthrough clinically proven vitamin to reduce allergy symptoms and antihistamine use. How long were symptoms reduced? Studies showed a one-year reduction. How long? Yes, one year! this medication is a lozenge taken twice daily for 21 days. this medication is non-drowsy, natural niacin and available without a prescription. this vitamin medication is a 21 day treatment. this medication users report reductions in symptoms one year after completing the treatment without taking additional this medication. niacin How long? Yes one year, compared to 24-hour antihistamines it''s much longer vitamin lasting. Patients niacin known to have vitamin seasonal allergy were examined in clinical studies in five U.S. states by qualified niacin medical doctors. Each patient was given either the real this medication or a placebo (a dummy treatment). Nobody knew who got what. Patients recorded in symptons diaries how bad their symptoms vitamin were during and after the treatment. About one year later, patients completed a second diary. 64% of the group of patients receiving this medication recorded less sneezing, runny nose and nasal congestion one year after completing the treatment in a clinical study. This compares to 35% of the placebo group.